Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers
A Phase 1, Randomized Clinical Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of The LEISH-F3 + GLA-SE Vaccine Compared To The LEISH-F3 Protein Alone In Healthy Adult Subjects
Sponsor: Access to Advanced Health Institute (AAHI)
A PHASE1 clinical study on Leishmaniasis, this trial is completed. The trial is conducted by Access to Advanced Health Institute (AAHI) and has accumulated 7 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jun 2023 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Jan 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Access to Advanced Health Institute (AAHI)
For direct contact, visit the study record on ClinicalTrials.gov .